Introduction The Flow Re-Direction Endoluminal Device (FRED; MicroVention) and its version dedicated for smaller vasculature FRED Jr. (MicroVention) belong to the worldwide most frequently used FD. Several studies showed a good efficacy of the FRED and FRED Jr. with a good safety profile in the short and mid-term. However, to date there are no targeted long term-follow-up data covering more than five years for these devices.

Aim of Study This study focuses on long-term outcomes after aneurysm treatment with either the FRED or the FRED Jr. to investigate the durability of treatment effect and long-term complications.

Methods Patients treated with either FRED or FRED Jr. between 2013 and 2017 at our institution, and thus a possibility for ≥5 years of follow-up, were retrospectively analysed. Aneurysm occlusion rates, recurrence rates, modified Rankin Scale score shifts to baseline, and delayed complications were assessed.

Results 68 patients with 84 aneurysms had long-term follow-up with a mean duration of 57.3 months. 44 patients harbouring 52 aneurysms had a follow-up ≥5 years with a mean follow-up period of 69.2 months. Complete occlusion was reached in 77.4% at two years and increased to 84.9% when the latest available imaging result was considered. After the two-years threshold, there were three reported symptomatic non-serious adverse events.

Conclusion This long-term follow-up study demonstrates that the FRED and FRED Jr. are safe and effective for the treatment of cerebral aneurysms in the long-term, with high rates of complete occlusion and low rates of delayed adverse events.

Disclosure of Interest Nothing to disclose.